Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 4, 2026Clinical Journal of the American Society of Nephrology

Henagliflozin reduces LVMI by ~5 g/m2 vs placebo in dialysis patients with HFpEF.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Does henagliflozin improve left ventricular mass index in dialysis patients with heart failure with preserved ejection fraction?

Population

112 dialysis patients with heart failure with preserved ejection fraction

Comparison

Henagliflozin added to conventional therapy for… vs Matching placebo added to conventional therapy…

Design

RCT, 1:1, double-blind, placebo-controlled

Follow-up

24 weeks

Key result

Henagliflozin significantly reduced left ventricular mass index compared to placebo in dialysis patients with HFpEF (mean difference -5.27 g/m2; 95% CI -10.02 to -0.53; P=0.03).

Authors

HYHao YanWWWei WangWWWangshu Wu

Discussion

Loading...

Member takes

Overview

Supports henagliflozin to reduce LV mass in dialysis HFpEF; extends SGLT2 inhibitor evidence to end-stage kidney disease.

Key Points

  • To assess the efficacy and safety of henagliflozin on cardiac structure in dialysis patients with heart failure with preserved ejection fraction (HFpEF).
  • Multicenter, randomized, double-blind, placebo-controlled trial assigning 112 dialysis patients with HFpEF (1:1) to henagliflozin (n=56) or placebo (n=56) for 24 weeks alongside conventional therapy.
  • The primary endpoint was the change in left ventricular mass index (LVMI) from baseline to week 24 evaluated in the intention-to-treat population using analysis of covariance.
  • Henagliflozin produced a significantly greater reduction in LVMI compared to placebo (least-squares mean change: -3.27±1.71 g/m² vs. 2.01±1.69 g/m²; between-group difference: -5.27 g/m², 95% CI: -10.02 to -0.53 g/m²; P=0.03).
  • No between-group differences occurred in secondary endpoints (LAVI, E/e', e', and NT-proBNP), and adverse event incidence was comparable between henagliflozin (36%) and placebo (34%).

Study Design

Type

RCT (n=112)

Blinding

Double-blind

Randomization

1:1

Multicenter

Yes

Structured PICO

Does henagliflozin improve left ventricular mass index in dialysis patients with heart failure with preserved ejection fraction?

P
Population
112 dialysis patients with heart failure with preserved ejection fraction (HFpEF) followed for 24 weeks.
I
Intervention
Henagliflozin added to conventional therapy for 24 weeks
C
Comparator
Matching placebo added to conventional therapy for 24 weeks
O
Outcome
Change in left ventricular mass index (LVMI) from baseline to week 24surrogate

Main Result

Mean Difference: -5.27 (95% CI -10.02–-0.53)

Absolute Event Rate: -3.27% vs 2.01%

p-value: p=0.03

In dialysis patients with HFpEF, the addition of henagliflozin to conventional therapy significantly reduced left ventricular mass index over 24 weeks without increasing adverse events.

Limitations

  • Small sample size requiring larger studies to confirm the LVMI-lowering effect
  • Larger studies are needed to confirm the LVMI-lowering effect

Cite This Study

Yan et al. (2026) conducted an RCT in Heart failure with preserved ejection fraction (HFpEF) in dialysis patients (n=112). Henagliflozin vs. Placebo was evaluated on Change in left ventricular mass index (LVMI) from baseline to week 24 (MD -5.27, 95% CI -10.02 to -0.53, p=0.03). Henagliflozin significantly reduced left ventricular mass index compared to placebo in dialysis patients with HFpEF (mean difference -5.27 g/m2; 95% CI -10.02 to -0.53; P=0.03).

synapsesocial.com/papers/6a9a85fa5d9e33f25c63162chttps://doi.org/10.2215/cjn.0000001201
View Full Paper
Ask AI
Bookmark
Share